← Leaderboards
Esma Alp
Kalocyte, Inc.
$3,204,667
Attributed
$3,916,275
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,916,275 · 3
By mechanism
R44$3,043,060 · 1
SB1$499,999 · 1
R43$373,216 · 1
Top collaborators
- Paul Werner Buehler1 shared
- Dipanjan Pan1 shared
Most similar at Kalocyte, Inc.
Same institution · by research overlap
- Jennifer P. Richards$833,728
- Nivesh Kumar Mittal$788,480
Others in their field
Other Emerging Leaders on “Reconstitution”
- Kathleen Maletic Neuzil · Emory University$27,203,974
- James Dale Berry · Brigham And Women'S Hospital$9,673,541
- Geoffrey Roger Hill · Fred Hutchinson Cancer Center$6,865,597
- Nikej Shah · Nirsum Laboratories, Inc.$4,866,388
- Radhika Subramanian · Massachusetts General Hospital$4,702,520
- Subba Shankar · Collamedix Inc.$4,628,486
Research focus
ReconstitutionErythrocytesNitric OxideProductionTransfusionCaringCost EffectiveLifeOxygenPreventHemorrhageSterilityHemoglobinFreeze DryingAffinityCell PhysiologyComplexInnovationBlood SubstitutesDesignBloodFailureAntioxidantsBiomaterial Compatibility
Grant awards (5)
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute$995,470
R44 · FY2025 · HL · contact PI
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute$997,590
R44 · FY2024 · HL · contact PI
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute$1,050,000
R44 · FY2023 · HL · contact PI
Manufacturing Scale-up, Purification, and Analytical Method Development, Validation and Qualification for KC1003, Key Precursor for ErythroMer (RBC substitute)$499,999
SB1 · FY2021 · HL · contact PI
Rapid Reconstitution of a Lyophilized, Bio-inspired, Artificial Red Blood Cell$373,216
R43 · FY2020 · HL · contact PI